Top

Paula R. Pohlmann, M.Sc., Ph.D.

Department of Breast Medical Oncology, Division of Cancer Medicine

Present Title & Affiliation

Primary Appointment

Chief, Clinical Research, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

Associate Professor (Joint appointment), Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2002	Universidade Federal do Rio Grande do Sul, Porto Alegre RS, BR, HPV and Cervix Cancer, Ph.D
2000	Universidade Federal do Rio Grande do Sul, Porto Alegre RS, BR, Clinical Sciences and Investigation, M.Sc
1992	Universidade Federal do Rio Grande do Sul, Porto Alegre RS, BR, MD

Postgraduate Training

2009-2011	Clinical Residency, Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
2006-2009	Clinical Fellowship, Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
2005-2006	Research Fellowship, Biomarker discovery and mAbs in the therapy for cancer, Vanderbilt University Medical Center, Nashville, Tennessee
2001-2003	ABM-AMRO Research Fellowship - Career Development Award, Translational Research on Breast Cancer and Tumor Immunology, Vrije Universiteit Medical Center, Amsterdam
1995-1997	Clinical Fellowship, Medical Oncology, Hospital de Clínicas Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS
1993-1994	Clinical Residency, Internal Medicine, Hospital de Clínicas Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS

Board Certifications

2013	American Board of Internal Medicine/ Subspecialty Hematology and Oncology
2012	American Board of Internal Medicine
1997	Brazilian Federal Board of Medicine (Conselho Federal de Medicina)
1995	Brazilian Federal Board of Medicine (Conselho Federal de Medicina)

Experience & Service

Academic Appointments

Associate Professor, Department of Medicine, Georgetown University, Washington, DC, 2018 - 2021

Assistant Professor, Department of Medicine, Vanderbilt University, Nashville, TN, 2011 - 2013

Faculty, Department of Oncology Post-Graduation Course, Associação Hospitalar Moinhos de Vento, Instituto de Educação e Pesquisa, Porto Alegre, RS, 2004 - 2005

Administrative Appointments/Responsibilities

Chair, Department of Medical Oncology, PRE-ISPY/I-SPY Phase Ib Program, 2020 - Present

Vice-Chair, Department of Medicine, Georgetown University, Washington, DC, 2019 - 2021

Leader/Physician Champion, Department of Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, 2018 - 2021

Board member, Immunonet Biosciences LLC, Murfreesboro, TN, 2015 - 2021

Organizer, Hospital Moinhos de Vento, Porto Alegre, RS, 2005 - 2005

Chief, Department of Medical Oncology, South American Office for Anticancer Drug Development (SOAD), Porto Alegre, RS, 2004 - 2005

Coordinator, Department of Unidade Sanitária Bom Jesus, Metropolitan Health Department, Porto Alegre, RS, 1999 - 2000

Coordinator, Department of Unidade Sanitária Bom Jesus, Metropolitan Health Department, Porto Alegre, RS, 1998 - 2000

Organizer, Hospital de Clinicas de Porto Alegre/Universidade Federal do Rio Grande do Sul and South American Office for Anticancer Drug Development (SOAD), Porto Alegre, RS, 1997 - 1997

Chief Medical Officer, Oncologic Treatment Group, Private Oncology and Chemotherapy Center, Porto Alegre, RS, 1997 - 2001

Organizer, Department of Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Ministry of Health of Brazil, Porto Alegre, RS, 1992 - 1992

Organizer, Department of Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Ministry of Health of Brazil, porto Alegre, RS, 1991 - 1991

Organizer, Department of Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Ministry of Health of Brazil, Porto Alegre, RS, 1991 - 1991

Organizer, Department of Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Ministry of Health of Brazil, Porto Alegre, RS, 1990 - 1990

Other Appointments/Responsibilities

Advisory board, Cancer Vaccines, CVC - Cancer Vaccine Coalition (NPO), 2024 - Present

Advisory board, LEAP Panel Round Table Consultation (GlobaL Expert Advisory HCP Panel), Pfizer, 2023 - 2024

Advisory Board, Abbvie, 2021 - 2021

Advisory Board, Anti-HER2 therapy, BOLT Biotherapeutics, 2021 - 2021

Steering Committee, global study SGNTUC-019, A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - Present

Advisory Board, Molecular diagnosis, CARIS Lifesciences, 2019 - 2019

NSABP Champion, Alliance A011502-A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial, Pittsburg, 2019 - 2024

Advisory Board, Liver embolization, Sirtex, 2019 - 2019

Advisory Board, Anti-HER2 therapy, Puma Biotechnology, 2018 - 2018

Advisory board, CINV - Chemotherapy Induced Nausea and Vomiting, Heron Therapeutics, 2017 - 2018

Senior Scientific Advisor, Brazilian Federation of Breast Health Support Philanthropic Institutions [Federacao Brasileira de Instituicoes Filantropicas de Apoio `a Saude da Mama]- FEMAMA, Porto Alegre, 2016 - 2018

Advisory board, CDK4/6 inhibition, Pfizer, 2016 - 2016

Advisory board, Molecular diagnosis, Personalized Cancer Therapy (Perthera), 2014 - 2022

Founder and Board Member, Immunonet Biosciences, LLC, Startup Company, Murfreesboro, TN, 2013 - 2021

Medical Advisor, Cancer Center Planning, Development and Recruiting, Hospital Daher, Brasilia, DF, 2003 - 2004

Founder, Hematology-Oncology, Oncologic Treatment Group, Private Oncology and Chemotherapy Center, Porto Alegre, RS, 1997 - 2001

Institutional Committee Activities

Faculty Advisor, Advisory Council for Clinical Research Leaders, 2024 - 2027

Leader, I-SPY Phase I Network/PRE-ISPY Program, 2021 - Present

Member, Steering Committee, 2020 - Present

Member, I-SPY2 Safety Working Group, 2020 - Present

Member, I-SPY2 DAPC - Data Access and Publication Committee, 2019 - Present

Member, Recruitment Committee, 2018 - 2021

Member, University Research Committee, 2018 - 2021

Member, I-SPY2 New Agents Committee, 2017 - Present

Member, Clinical Research Committee, 2014 - 2021

Member, Quality and Practice Council, 2014 - 2018

Member, Faculty Search Committee, 2013 - 2021

Member, Selection Committee, 2013 - 2021

Member, Selection Committee, 2012 - 2013

Member, Selection Committee, 2012 - 2012

Member, Faculty Search Committee, 2012 - 2013

Member, Steering Committee, 2012 - 2013

Advisor, IMG Advisors Network (IAN), 2010 - 2014

Evaluator, PhD Defense Committee, 2005 - 2005

Evaluator, MS Evaluation Committee, 2005 - 2005

Member, Recruiting Committee, Process # 393 – for Physician, Specialty Pediatrics, 2000 - 2000

Evaluator, Graduation Committee, 1997 - 1997

Honors & Awards

2021	Teacher of the Year: Hematology-Oncology Fellows Class 2021, Division of Hematology and Oncology, MedStar Georgetown University Hospital, MedStar Georgetown University Hospital
2021	Castle Connolly Regional Top Doctor, Castle Connolly, Washington DC
2014	Finalist, First Diaspora Brazil Award – Health Care Technology, Brazilian Agency for Industrial Development, the Ministry of Industrial Development and Commerce and the Ministry of Foreign Affairs
2014	Teacher of the Year: Hematology-Oncology Fellows Class 2014, Division of Hematology and Oncology, MedStar Georgetown University Hospital
2013	Most Outstanding Poster Presentation, 12th Annual Cancer Retreat, “Routine multiplexed mutational analysis of colorectal cancers – the updated Vanderbilt experience”, Meharry Medical College/Vanderbilt Ingram Cancer Center/Tennessee State University Cancer Partnership
2012	People’s Choice Winner, Life Sciences/Healthcare Track, “Diagnostic tool for predicting patient responses to therapeutic antibodies”, 2012 TN Governor's Innovation Conference
2012	Second Prize, the 2012 Tech Venture Challenge: “Diagnostic tool for predicting patient responses to therapeutic Abs”, Vanderbilt University
2009	Most Outstanding Fellow Award, Clinical Fellow, Division of Hematology-Oncology, Vanderbilt University
2009	Most Outstanding Poster, 2009 VICC Retreat, “Anti-trastuzumab antibodies are associated with response to trastuzumab in mice and with longer progression free survival in patients treated with trastuzumab”, Vanderbilt-Ingram Cancer Center
2007	Shining Star Award, Clinical Fellow, Division of Hematology-Oncology, Vanderbilt University
2006	Honorable Mention, 2006 VICC Retreat, for Excellence in Cancer Research and Outstanding Poster Presentation: “Influence of the immune network on antibody-based anti-cancer therapy in a mouse model”, Vanderbilt-Ingram Cancer Center
2002	Professor Albert Sabin Medal (Comenda Medalha Professor Albert Sabin), Sociedade Cívica Cultural Brasileira – SCCB, National Campaign for Health Care Enhancement
2001	Women’s Personality of the Year 2001 - Medicine (Troféu Mulher Destaque 2001 - Medicina), Rede Brasil Sul de Telecomunicacoes - RBS TV, Grêmio Náutico União
1995	Young Investigator Award, Sociedade Brasileira de Oncologia Clinica (SBOC)
1995	Honored Fellow, Class ATM 95/1, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS)
1992	Magna Cum Laudae at Medical School, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS)
1992	President of Class, Universidade Federal do Rio Grande do Sul (UFRGS)
1988	Medical Student Liaison, Course Advisory Board, Faculdade de Medicina Universidade Federal do Rio Grande do Sul (UFRGS)

Selected Publications

Peer-Reviewed Articles

Piha-Paul S, Olwill SA, Hamilton E, Tolcher A, Pohlmann P, Liu SV, Wurzenberger C, Hasenkamp LC, Hansbauer EM, Shroff R, Hurvitz S, Krishnamurthy A, Patnaik A, Hahn N, Kumar R, Duerr M, Zettl M, Aviano K, Matis L, Bruns I, Ku G. A First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies. Clin Cancer Res, 2024. e-Pub 2024. PMID: 39235868.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Winer EP, Krop IE, Tolaney SM. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol:JCO2302170, 2024. e-Pub 2024. PMID: 38935923.
Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Clin Cancer Res 30(11):2444-2451, 2024. e-Pub 2024. PMID: 38470545.
Lindgren ES, Yan R, Cil O, Verkman AS, Chan MF, Seitzman GD, Farooq AV, Huppert LA, Rugo HS, Pohlmann PR, Lu J, Esserman LJ, Pasricha ND. Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs). Curr Ophthalmol Rep 12(2):13-22, 2024. e-Pub 2024. PMID: 38756824.
Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM, Irvin WJ, Symington B, Visvanathan K, Pohlmann PR, Openshaw TH, Weiss A, Winer EP, Carey LA, Holmes MD. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial. JAMA 331(20):1714-1721, 2024. e-Pub 2024. PMID: 38683596.
DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov 14(5):828-845, 2024. e-Pub 2024. PMID: 38358339.
Wang H, Yee D, Potter D, Jewett P, Yau C, Beckwith H, Watson A, O'Grady N, Wilson A, Brain S, Pohlmann P, Consortium IT, Blaes A. Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial. Breast Cancer Res Treat 204(3):589-97, 2024. e-Pub 2024. PMID: 38216819.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nat Commun 15(1):2691, 2024. e-Pub 2024. PMID: 38538574.
Tozbikian G, Krishnamurthy S, Bui MM, Feldman M, Hicks DG, Jaffer S, Khoury T, Wei S, Wen H, Pohlmann P. Emerging landscape of targeted therapy of breast cancers with low HER2 protein expression. Arch Pathol Lab Med 48(2):242-55, 2024. e-Pub 2024. PMID: 37014972.
Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppe JP, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Rep Med 4(12):101312, 2023. e-Pub 2023. PMID: 38086377.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. medRxiv, 2023. e-Pub 2023. PMID: 38105958.
Nakamura Y, Mizuno N, Sunakawa Y, Hamilton EP, Hayashi H, Kim ST, Lee KW, Monk BJ, Nguyen D, Okines AFC, O'Malley DM, Pohlmann PR, Reck M, Yu EY, Groisberg R, Ramos J, Tan O, Stinchcombe T, Bekaii-Saab TS. Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study. J Clin Oncol, 2023. e-Pub 2023. PMID: 37751561.
Roy T, Barrows E, Mainor C, Collins J, Lynce F, Isaacs C, Pohlmann PR. A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor. Contemp Clin Trials Commun 33:101110, 2023. e-Pub 2023. PMID: 37026029.
Wang H, Yee D, Potter D, Jewett P, Yau C, Beckwith H, Watson A, O'Grady N, Wilson A, Brain S, Pohlmann P, Blaes A. Impact of Body Mass Index on Pathological Response after Neoadjuvant Chemotherapy: Results from the I-SPY 2 trial. Res Sq, 2023. e-Pub 2023. PMID: 37397981.
Xiao J, Sharma U, Arab A, Miglani S, Bhalla S, Suguru S, Suter R, Mukherji R, Lippman ME, Pohlmann PR, Zeck JC, Marshall JL, Weinberg BA, He AR, Noel MS, Schlegel R, Goodarzi H, Agarwal S. Propagated Circulating Tumor Cells Uncover the Potential Role of NFkappaB, EMT, and TGFbeta Signaling Pathways and COP1 in Metastasis. Cancers (Basel) 15(6), 2023. e-Pub 2023. PMID: 36980717.
Pohlmann PR, Graham D, Wu T, Ottaviano Y, Mohebtash M, Kurian S, McNamara D, Lynce F, Warren R, Dilawari A, Rao S, Mainor C, Swanson N, Tan M, Isaacs C, Swain SM. HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. Breast Cancer Res Treat 196(3):571-581, 2022. e-Pub 2022. PMID: 36280642.
Chen WY, Ballman KV, Winer EP, Openshaw TH, Hahn OM, Briccetti FM, Irvin WJ, Pohlmann PR, Carey LA, Partridge AH, Weiss A, McCall LM, Matyka C, Carvan M, Holmes MD. A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial. J Clin Oncol 40(36 Supplement), 2022. e-Pub 2022.
Heeke AL, Elliott A, Feldman R, O'Connor HF, Pohlmann PR, Lynce F, Swain SM, Nunes MR, Magee D, Oberley MJ, Swenson J, Vidal G, Isaacs C, Schwartzberg L, Korn WM, Tan AR. Molecular characterization of ESR1 variants in breast cancer. Breast Cancer Res Treat 196(2):279-289, 2022. e-Pub 2022. PMID: 36125660.
Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, Investigators I, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell 40(6):609-23, 2022. e-Pub 2022. PMID: 35623341.
O'Keefe K, Elliott A, Livasy C, Steiner M, Kang I, Hoon DSB, Korn WM, Walker P, Radovich M, Pohlmann PR, Swain SM, Tan AR, Heeke AL. HER2 alterations and prognostic implications in all subtypes of breast cancer. J Clin Oncol 40(16 Supplement):1041, 2022. e-Pub 2022.
Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer 8(1):18, 2022. e-Pub 2022. PMID: 35173164.
Jones BC, Sengupta S, Sevigny CM, Jin L, Pohlmann PR, Shajahan-Haq, Clarke R. Pfkfb3 inhibition significantly decreases endocrine-resistant breast cancer growth and induces necroptotic cell death. Cancer Res 82(4 Supplement), 2022. e-Pub 2022.
Lynce F, Mainor C, Geng X, Jones G, Schlam I, Wang H, Feger U, Donahue R, Toney N, Jochems C, Schlom J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Dilawari AA, Chitalia Am Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Swain SM, Parsons HA, Pohlmann P, Isaacs C. Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study. Cancer Res 82(4 Supplement), 2022. e-Pub 2022.
Pohlmann PR, Graham D, Wu T, Ottaviano Y, Mohebtash M, Kurian S, McNamara D, Lynce F, Warren R, Dilawari A, Rao S, Mainor C, Swanson N, Tan M, Isaacs C, Swain SM. Halt-d: A randomized open label phase 2 study of crofelemer for the prevention of chemotherapy induced diarrhea (cid) in patients with breast cancer receiving trastuzumab, pertuzumab, and a taxane. Cancer Res 82(4 Supplement), 2022. e-Pub 2022.
Okines A, Pohlmann PR, Ramos J, Walker L, Hamilton E. SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: HER2-mutated breast cancer cohort (ongoing clinical trial) [abstract]. Cancer Res 82(4 Supplement), 2022. e-Pub 2022.
Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer 7(1):131, 2021. e-Pub 2021. PMID: 34611148.
Lynce F, Blackburn MJ, Zhuo R, Gallagher C, Hahn OM, Abu-Khalaf M, Mohebtash M, Wu T, Pohlmann PR, Dilawari A, Tiwari SR, Chitalia A, Warren R, Tan M, Shajahan-Haq AN, Isaacs C. Hematological safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer 127(19):3622-3630, 2021. e-Pub 2021. PMID: 34157782.
ynce F, Blackburn MJ, Zhuo R, Gallagher C, Hahn OM, Abu-Khalaf M, Mohebtash M, Wu T, Pohlmann PR, Dilawari A, Tiwari SR, Chitalia A, Warren R, Tan M, Shajahan-Haq AN, Isaacs C. Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer 127(19):3622-30, 2021. e-Pub 2021. PMID: 34157782.
Ruddy KJ, Zheng Y, Tayob N, Hu J, Dang CT, Yardley DA, Isakoff SJ, Valero VV, Faggen MG, Mulvey TM, Bose R, Sella T, Weckstein DJ, Wolff AC, Reeder-Hayes KE, Rugo HS, Ramaswamy B, Zuckerman DS, Hart LL, Gadi VK, Constantine M, Cheng KL, Briccetti FM, Schneider BP, Merrill Garrett A, Kelly Marcom P, Albain KS, DeFusco PA, Tung NM, Ardman BM, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Rosenberg S, DeMeo MK, Burstein HJ, Winer EP, Krop IE, Partridge AH, Tolaney SM. Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat 189(1):103-110, 2021. e-Pub 2021. PMID: 34120223.
Xiao J, Pohlmann PR, Isaacs C, Weinberg BA, He AR, Schlegel R, Agarwal S. Circulating tumor cells: technologies and their clinical potential in cancer metastasis. Biomedicines 9(9):1111, 2021. e-Pub 2021. PMID: 34572297.
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol 39(21):2375-2385, 2021. e-Pub 2021. PMID: 34077270.
Khoury K, Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Asch F, Tan M, Isaacs C, Swain SM. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Res Treat 185(3):863-868, 2021. e-Pub 2021. PMID: 33400034.
Heeke AL, Xiu J, Elliott A, Korn WM, Lynce F, Pohlmann PR, Isaacs C, Swain SM, Vidal G, Schwartzberg LS, Tan AR. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. Breast Cancer Res Treat 184(2):265-275, 2020. e-Pub 2020. PMID: 32776290.
Xiao J, McGill JR, Stanton K, Kassner JD, Choudhury S, Schlegel R, Sauna ZE, Pohlmann PR, Agarwal S. Efficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 32998338.
Harris MA, Conkright B, Johnson R, Boca SM, Riazi S, Torguson R, Alaoui A, Bhuvaneshwar K, Gusev Y, Asch FM, Pohlmann PR, Barac A, Madhavan S. Cardiovascular Phenotyping in Breast Cancer Patients Treated with Her2 Targeted Therapies Using Informatics Approaches. Research Square Version 1, 2020. e-Pub 2020.
Khoury K, Tan AR, Elliott A, Xiu J, Gatalica Z, Heeke AL, Isaacs C, Pohlmann PR, Schwartzberg LS, Simon M, Korn WM, Swain SM, Lynce F. Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer. Front Oncol 10:1475, 2020. e-Pub 2020. PMID: 32983983.
Pishvaian MJ, Blais EM, Bender RJ, Rao S, Boca SM, Chung V, Hendifar AE, Mikhail S, Sohal DPS, Pohlmann PR, Moore KN, He K, Monk BJ, Coleman RL, Herzog TJ, Halverson DD, DeArbeloa P, Petricoin EF 3rd, Madhavan S. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open 2(4):505-515, 2019. e-Pub 2019. PMID: 32025647.
Lynce F, Wang H, Petricoin EF, Pohlmann PR, Smaglo B, Hwang J, He AR, Subramaniam DS, Deeken J, Marshall J, Pishvaian MJ. A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. Cancer Chemother Pharmacol 84(5):1145-1151, 2019. e-Pub 2019. PMID: 31538230.
Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq A, Tan MT, Isaacs C, Swain SM. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat 175(3):595-603, 2019. e-Pub 2019. PMID: 30852761.
Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 37(13):1081-1089, 2019. e-Pub 2019. PMID: 30860945.
Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, Zhang W, Iizuka K, Foster PG, Molinero L, Funke R, Powderly J. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol 5(3):334-342, 2019. e-Pub 2019. PMID: 30347025.
Lynce F, Saleh M, Shajahan-Haq A, Gallagher C, Dilawari A, Hahn O, Abu-Khalaf M, Cai L, Pohlmann P, Mohebtash M, Kamugisha L, Isaacs C. PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Contemp Clin Trials Commun 10:190-192, 2018. e-Pub 2018. PMID: 30009277.
Lynce F, Blackburn MJ, Cai L, Wang H, Rubinstein L, Harris P, Isaacs C, Pohlmann PR. Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials. Breast Cancer Res Treat 168(1):35-41, 2018. e-Pub 2018. PMID: 29119354.
Pohlmann PR, Isaacs C. Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few. J Natl Cancer Inst 110(1):3-5, 2018. e-Pub 2018. PMID: 28922782.
Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sanchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res 77(9):2488-2499, 2017. e-Pub 2017. PMID: 28249908.
Yan HP, Roberts LJ, Davies SS, Pohlmann P, Parl FF, Estes S, Maeng J, Parker B, Mernaugh R. Isolevuglandins as a gauge of lipid peroxidation in human tumors. Free Radic Biol Med 106:62-68, 2017. e-Pub 2017. PMID: 28189846.
Gao JJ, Tan M, Pohlmann PR, Swain SM. HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens. Clin Breast Cancer 17(1):76-78, 2017. e-Pub 2017. PMID: 27692565.
Mahajan AS, Sugita BM, Duttargi AN, Saenz F, Krawczyk E, McCutcheon JN, Fonseca AS, Kallakury B, Pohlmann P, Gusev Y, Cavalli LR. Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors. PLoS One 12(10):e0186190, 2017. e-Pub 2017. PMID: 29049316.
Robinson BN, Newman AF, Tefera E, Herbolsheimer P, Nunes R, Gallagher C, Randolph-Jackson P, Omogbehin A, Dilawari A, Pohlmann PR, Mohebtash M, Lee Y, Ottaviano Y, Mohapatra A, Lynce F, Brown R, Mete M, Swain SM. Video intervention increases participation of black breast cancer patients in therapeutic trials. NPJ Breast Cancer 3:36, 2017. e-Pub 2017. PMID: 28944289.
Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, Investigators I. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med 375(1):23-34, 2016. e-Pub 2016. PMID: 27406347.
Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, Investigators I. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med 375(1):11-22, 2016. e-Pub 2016. PMID: 27406346.
Madhavan S, Aisner DL, Sheahan L, Sood N, Reddy S, Picora A, Wilhelm E, Volk J, Cusano D, Lucia K, Pohlmann PR, Marshall JL. Barriers to Implementation of Precision Medicine for Cancer Treatment in the U.S. Healthcare System. The Journal of Precision Medicine:48-56, 2016. e-Pub 2016.
Shah AT, Demory Beckler M, Walsh AJ, Jones WP, Pohlmann PR, Skala MC. Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma. PLoS One 9(3):e90746, 2014. e-Pub 2014. PMID: 24595244.
Grothey A, Pohlmann PR. Expert Point of View: Three Molecular Subtypes of Colorectal Cancer Identified. The ASCO Post 4(6), 2013. e-Pub 2013.
Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, Chung CH. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One 5(9):e12702, 2010. e-Pub 2010. PMID: 20856931.
Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 15(24):7479-7491, 2009. e-Pub 2009. PMID: 20008848.
Caleffi M, Ribeiro RA, Duarte Filho DL, Ashton-Prolla P, Bedin AJ, Skonieski GP, Zignani JM, Giacomazzi J, Franco LR, Graudenz M, Pohlmann P, Fernandes JG, Kivitz P, Weber B. A model to optimize public health care and downstage breast cancer in limited-resource populations in southern Brazil. (Porto Alegre Breast Health Intervention Cohort). BMC Public Health 9:83, 2009. e-Pub 2009. PMID: 19284670.
Menke CH, Pohlmann PR, Backes A, Cericatto R, Oliveira M, Bittelbrunn A, Schwartsmann G. Tumor size as a surrogate end point for the detection of early breast cancer: a 30-year (1972-2002), single-center experience in southern Brazil. Breast J 13(5):448-56, 2007. e-Pub 2007. PMID: 17760665.
Schwartsmann G, DiLeone LP, Horowitz M, Schunemann D, Cancella A, Pereira AS, Richter M, Souza F, da Rocha AB, Souza FH, Pohlmann P, De Nucci G. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 24(5):403-12, 2006. e-Pub 2006. PMID: 16505950.
Toebak MJ, Pohlmann PR, Sampat-Sardjoepersad SC, von Blomberg BM, Bruynzeel DP, Scheper RJ, Rustemeyer T, Gibbs S. CXCL8 secretion by dendritic cells predicts contact allergens from irritants. Toxicol In Vitro 20(1):117-24, 2006. e-Pub 2006. PMID: 16099135.
Middelburg R, de Haas RR, Dekker H, Kerkhoven RM, Pohlmann PR, Fuentes-Alburo A, Mohar A, Pinedo HM, Lankelma J. Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res 11(5):1863-9, 2005. e-Pub 2005. PMID: 15756011.
Rosa DD, Medeiros LR, Bozzetti MC, Edelweiss MI, Pohlmann PR, Stein, AT. Adjuvant chemotherapy for early-stage cervix cancer (Protocol). The Cochrane Database of Systematic Reviews 3:1-8, 2005. e-Pub 2005.
Medeiros LR, Rosa DD, Bozzetti MC, Edelweiss MI, Stein AT, Pohlmann PR, Zelmanowicz AM, Ethur AB, Zanini RR. Laparoscopy versus laparotomy for FIGO stage I ovarian cancer (Protocol). The Cochrane Database of Systematic Reviews 3:1-12, 2005. e-Pub 2005.
Pohlmann PR, Suchil Bernal L, Fuentes Alburo A, Buter J, Gallardo Rincon D, Mohar A, Mayordomo JI, van der Hoeven JJM, van der Wall E, de Gruijl T, Pinedo HM. Prolonged neoadjuvant treatment plus GM-CSF in locally advanced breast cancer: Clinical and biological concepts. Rev Oncol (Clinical and Translational Oncology) 6(3):130-9, 2004. e-Pub 2004.
Pinedo HM, Buter J, Luykx-de Bakker SA, Pohlmann PR, van Hensbergen Y, Heideman DA, van Diest PJ, de Gruijl TD, van der Wall E. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells. Eur J Cancer 39(8):1061-7, 2003. e-Pub 2003. PMID: 12736104.
Pohlmann P, DiLeone LP, Cancella AI, Caldas AP, Dal Lago L, Campos O, Monego E, Rivoire W, Schwartsmann G. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 25(5):496-501, 2002. e-Pub 2002. PMID: 12393992.
Venegas LF, Pohlmann PR, Balbinot AL, Schuck E, Oliveira CTM, Frank KJ, Dillemburg CF, da Costa MS, Rivero LF, Putten ACK. Primary splenic angiosarcoma: case report and literature review. Rev Bras Cancerol 44(1):51-6, 1998. e-Pub 1998.
Schwartsmann G, Mans DR, Menke CH, Xavier N, Caleffi M, Ferreira Filho AF, Schunemann H, Kalakun L, Koya R, Pohlman P, Venegas LF. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer. Oncology (Williston Park) 11(4 Suppl 3):24-9, 1997. e-Pub 1997. PMID: 9144687.
Daudt AW, Prolla JC, Dietz J, Grassi PR, Arnt CA, Loss JF, Costa LA, Pohlmann PR. Tobacco-related diseases: a 21-year study (1970-1990) of the mortality rate in the state of Rio Grande do Sul, Brazil. The Journal of Smoking-Related Disorders 4(3):155-63, 1993. e-Pub 1993.
Loss JF, Pohlmann PR. Aspectos Emocionais da Síndrome da Imunodeficiência Adquirida em Pediatria. Revista de Medicina ATM 13:164-8, 1992. e-Pub 1992.
Pohlmann PR, Loss JF, Marzola B, Polanczyk CA, Zampese MS, Kronfeld M. Sarcoma de Kaposi e SIDA - HCPA: avaliação da sobrevida. Revista de Medicina ATM 13:76-80, 1992. e-Pub 1992.
Pohlmann PR, Loss JF, Barrionuevo AA. Estudantes de Medicina: III. O que sabem sobre a organização do sistema de saúde?. Revista de Medicina ATM 13:70-5, 1992. e-Pub 1992.
Barrionuevo AA, Pohlmann PR, Loss JF. Estudantes de Medicina: I. Aprendizado dos procedimentos básicos fundamentais à medicina. Revista de Medicina ATM 13:59-4, 1992. e-Pub 1992.
Loss JF, Barrionuevo AA, Pohlmann PR. Estudantes de Medicina: II. Informações e medo da SIDA. Revista de Medicina ATM 13:65-9, 1992. e-Pub 1992.
Pohlmann PR, Loss JF, Flores C, Bolzzoni A, Duncan BB, Zimmer PM. Tabagismo em Porto Alegre: prevalencia e o papel dos profissionais da saude na prevencao. AMB Rev Assoc Med Bras 37(1):8-14, 1991. e-Pub 1991. PMID: 1658870.

Invited Articles

Xiao J, Pohlmann PR, Isaacs C, Weinberg BA, He AR, Schlegel R, Agarwal S. Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis. Biomedicines 30(9):1111, 2021. e-Pub 2021. PMID: 34572297.
Gallanis GT, Pericas RI, Riegel AT, Pohlmann PR. An evaluation of palbociclib as a breast cancer treatment option: a current update. Expert Opin Pharmacother 22(3):281-90, 2021. e-Pub 2021. PMID: 33198527.

Abstracts

Torrado C, Brink A, Gouda MA, Kang L, Osburn J, Patterson CJ, Poullard A, Urschel GE, Dumbrava EE, Karp DD, Naing A, Piha-Paul SA, Pohlmann PR, Ahnert JR, Tsimberidou AM, Yap TA, Hong DS, Meric-Bernstam F, Fu S, Charles S. Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated phase I department at The University of Texas MD Anderson Cancer Center. J Clin Oncol 42(16):Poster Board #506, 2024. e-Pub 2024.
Gouda MA, Lin HY, Kang L, Le H, Dumbrava EE, Fu S, Karp DD, Tsimberidou AM, Naing A, Piha-Paul SA, Pohlmann PR, Ahnert JR, Yap TA, Meric-Bernstam F, Hong DS. Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors. J Clin Oncol 42(16):Poster Board #244, 2024. e-Pub 2024.
Pohlmann PR, Potter DA, Chen N, Mouabbi JA, Rampurwala M, Rayani S, Tan AR, Leon-Ferre RA, Giridhar K, Boughey JC, Han HS, Kennedy LC, Walsh EM, Tripathy D, Jafari S, Eklund M, Nanda R, Meric-Bernstam F, Yee D, and Esserman L. PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1). J Clin Oncol 42(16), 2024. e-Pub 2024.
Fergus KB, Middha P, Quandt Z, Shieh Y, Basu AB, Sayaman R, Pohlmann PR, Yee D, Shatsky RA, Isaacs C, Campbell MJ, Hirst GL, Swigart LB, van 't Veer L, Ziv E, Esserman L. Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial. J Clin Oncol 42(16):Poster Board #127, 2024. e-Pub 2024.
Torrado C, Rai K, Moawad M, Dumbrava EE, Fu S, Hong DS, Karp DD, Meric-Bernstam F, Naing A, Pohlmann PR, Ahnert JR, Tsimberidou AM, Yap TA, Said R, Pelosof LC, Piha-Paul SA. A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449). J Clin oncol 42(16), 2024. e-Pub 2024.
Pegram MD, Calfa C, Chen C, Salgado AC, heeke AL, Kang I, Pistilli B, Pohlmann PR, Rugo HS, Saura C, Vicier C, Pearson C, Mangeshkar M, Yu T, Alonso MN, Colburn DE, Perez EA, Drago JZ. Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd). J Clin Oncol 42(16):Poster Session. Poster Board #98b, 2024. e-Pub 2024.
Abdou Y, Pohlmann PR, Maziarz RT, Murthy HS, Yuan Y, Krishnamurthy A, Reiss KA, Isaacs J, Blumenthal D, Gabitova L, Menchel B, Locke K, Wetzel J, Klichinsky M, Cushing D, Condamine T, Sohal D. A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors. J Clin Oncol:Poster Board #154b, 2024. e-Pub 2024.
Okines AFC, Curigliano G, Mizuno N, Oh DY, Rorive A, Soliman HH, Takahashi S, Bekaii-Saab TS, Hamilton EP, Monk BJ, Nakamura Y, Nguyen D, O'Malley DM, Reck M, Yu EY, Ramos J, Tan S, Stinchcombe T, Pohlmann PR. Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study. J Clin Oncol 42(16), 2024. e-Pub 2024.
Lynce F, Shimada K, Geng X, Richardson ET, Mainor C, Wei M, Collins JM, Pohlmann PP, Heeke AL, Zheng KF, Townsend M, Staunton J, Schnitt SJ, Brugge JS, Wang H, Isaacs C, Shapiro GI, Guerriero JL. TALAVE: Induction talazoparib (tala) followed by combined tala and avelumab in patients (pts) with advanced breast cancer (ABC). Cancer Res 83(8), 2023. e-Pub 2023.
Abdou Y, Dees EC, Mortimer JE, Pohlmann PR, Johnson ML, Maziarz RT, Specht JM, Yuan Y, Ueno NT, Angelos M, Gill S, Ronczka A, Condamine T, Cushing D, Barton D, Klichinsky M, Swaby RF, Reiss KA. A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors. J Clin Oncol 41(16), 2023. e-Pub 2023.
Mainor CB, Barrows ED, Wang H, Lynce F, Asahi N, Collins JM, Swanson N, Castle J, Novielli A, Slingerland J, Isaacs J, Pohlmann PR. A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i). J Clin Oncol 41(16), 2023. e-Pub 2023.
Hurvitz SA, Hamilton EP, Spira AI, Pohlmann PR, Giordano A, Clifton K, Anderson BD, Dutta S, Mangipudi U, Saini S, Palacino J, Karunaratne T, Greensmith D, Christensen O, Wilks S. A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors. J Clin Oncol 41(16), 2023. e-Pub 2023.
Rugo HS, Wolf DM, Yau C, Petricoin E, Pohlmann PR, Pusztai L, Symmans WFF, Borowsky A, Finestone S, Yee D, Hylton N, van 't Veer L, Esserman L, DeMichele A. Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival. J Clin Oncol 41(16), 2023. e-Pub 2023.
Nakamura Y, Mizuno N, Sunakawa Y, Hamilton EP, Hayashi H, Kim ST, Lee KW, Monk BJ, Nguyen D, Okines AFC, O'Malley DM, Pohlmann PR, Reck M, Yu EY, Groisberg R, Ramos J, Tan O, Stinchcombe T, Bekaii-Saab TS. Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study. J Clin Oncol 41(16), 2023. e-Pub 2023.
Chen WY, Ballman KV, Winer EP, Openshaw TH, Hahn OM, Briccetti FM, Irvin WJ, Pohlmann PR, Carey LA, Partridge AH, Weiss A, McCall LM, Matyka C, Carvan M, Holmes MD. A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) trial. ASCO Virtual Plenary, 2022. e-Pub 2022.
Pohlmann PR. Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: HER2-mutated breast cancer cohort (Trial in Progress). 2021 ESMO Breast Cancer Virtual Congress, 2021. e-Pub 2021.
Stinchcombe T, Monk BJ, Okines AFC, Pohlmann PR, Yu EY, Bekaii-Saab TS, Nakamura Y, O'Malley DM, Kang V, Walker LN, Reck M. Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress). 2021 Annual American Society of Clinical Oncology (ASCO) Meeting, 2021. e-Pub 2021.
Hamilton E, Reinisch M, Loi S, Okines A, Pohlmann PR, Brix EH, Bourgeois H, Yeo B, Aylesworth C, Cobleigh M, Goncalves A, Moroose R, Tkaczuk KHR, Tsai M, Simmons C, Andersson M, Soliman H, Cairo M, Carey LA, Cameron D, Ramos J, Feng W, and Oliveira M. Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status. 2020 Annual San Antonio Breast Cancer Symposium (SABCS), 2020. e-Pub 2020.
Dumbrava EI, Sharma MR, Carvajal RD, Catenacci D, Emens LA, Gadgeel SM, Hanna GJ, Juric D, Kang YK, Lee J, Lee KW, Li BT, Moore K, Pegram MD, Pohlmann PR, Rasco D, Spira A, Tan AR, Ackerman SE, LeBlanc H, Dornan D, Kowanetz M, Alonso MN, Perez EA. Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. 2020 Annual San Antonio Breast Cancer Symposium (SABCS), 2020. e-Pub 2020.
Murthy R, O’Brien B, Berry D, Navin N, Johnson J, Gule-Monroe M, Leone J, Specht J, Melisko M, Morikawa A, Storniolo A, Brufsky A, Pohlmann P, Park D, Park B, Krop I, Lin N, Rimawi M, Wolff A, Forero-Torres A, Stringer-Reasor E. A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2-positive breast cancer. 2020 Annual Society for Neuro-Oncology (SNO) Meeting, 2020. e-Pub 2020.
Lander EM, Lehmann BD, Shah PD, Dees EC, Ballinger TJ, Pohlmann PR, Santa-Maria CA, Shyr Y, Mayer IA, Park BH, Pietenpol JA, Abramson VG. A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC). 2020 Annual American Society of Clinical Oncology (ASCO) Virtual Scientific Program, 2020. e-Pub 2020.
Vidula N, Nanda R, Miller K, Pohlmann PR, Abramson VG, Emens LA, Park BH, Liu NC, Goga A, Rugo HS. Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial. 2020 Annual American Society of Clinical Oncology (ASCO) Virtual Scientific Program, 2020. e-Pub 2020.
Khoury K, Barac A, Lynce F, Geng X, Dang CT, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer PM, Warren RD, Srichai MB, Hofmeyer M, Asch FM, Tan MT, Isaacs C, Swain SM. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function. 2020 Annual American Society of Clinical Oncology (ASCO) Virtual Scientific Program, 2020. e-Pub 2020.
Piha-Paul S, Bendel J, Tolcher A, Hurvitz S, Patnaik A, Shroff R, Pohlmann P, Zettl M, Hahn N, Krishnamurthy A, Duerr M, Mei J, Aviano K, Yusuf R, Matis L, Olwill S, Bruns I, Ku G. O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies. JITC 8(1), 2020. e-Pub 2020.
Vidula N, Nanda R, Miller K, Abramson V, Pohlmann P, Brufsky A, Park B, Liu M, Goga A, and Rugo HS. Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC) 44 trial. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019. e-Pub 2019.
Assad H, Hart I, Purrington K, Xiu J, Pohlmann PR, Swain S, Vidal G, Simon M. Somatic genomic profiles of breast tumors differ by BRCA1 and BRCA2 variants of unknown significance status. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019. e-Pub 2019.
Pohlmann PR, Yau C, DeMichele A, Isaacs C, Boughey JC, Hylton N, Melisko ME, Perlmutter J, Rugo HS, Symmans W, Consortium IT, Berry DA, Esserman L. Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019. e-Pub 2019.
Lynce F, Zhuo R, Blackburn M, Gallagher C, Hahn O, Abu-Khalaf M, Mohebtash M, Wu T, Pohlmann P, Dilawari A, Tiwari S, Chitalia A, Warren R, Tan M, Shajahan-Haq A, and Isaacs C. Safety of palbociclib in African American women with hormone receptor positive HER2 negative advanced breast cancer and benign ethnic neutropenia: PALINA study. 2019 Annual San Antonio Breast Cancer Symposium (SABCS), 2019. e-Pub 2019.
Wulfkuhle JD, Wolf DM, Yau C, Gallagher RI, Swigart LB, Hirst GL, Yee D, Pohlmann PR, Elias AD, Moulder SL, Tripathy D, DeMichele A, Esserman L, Berry DA, van 't Veer L, Petricoin E, Investigators I. HER family protein expression and activation predict response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL. 2019 Annual American Society of Clinical Oncology (ASCO) Meeting, 2019. e-Pub 2019.
Heeke AL, Xiu J, Lynce F, Pohlmann PR, Vidal GA, Isaacs C, Swain SM, Schwartzberg LS, Tan AR. Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. 2019 Annual American Society of Clinical Society (ASCO) Meeting, 2019. e-Pub 2019.
Khoury K, Feldman R, Pohlmann PR, Heeke AL, Gatalica Z, Veloso Y, Vidal GA, Schwartzberg LS, Swain SM, Isaacs C, Lynce F. Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC). J Clin Oncol, 2019. e-Pub 2019.
Vidula N, Goga A, Hwang J, Liu MC, Park BH, Nanda R, Pohlmann PR, Storniolo AM, Brufsky A, Abramson V, Rugo HS. A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies. 2018 Annual San Antonio Breast Cancer Symposium (SABCS), 2018. e-Pub 2018.
Khoury K, Isaacs C, Gatti-Mays ME, Donahue RN, Schlom J, Wang H, Gallagher C, Graham D, Warren R, Dilawari A, Swain SM, Pohlmann PR, Lynce F. Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study. 2018 Annual San Antonio Breast Cancer Symposium (SABCS), 2018. e-Pub 2018.
Lynce F, Barac A, Geng X, Dang CT, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer PM, Warren RD, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq AN, Tan MT, Isaacs C, Swain SM. SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function. 2018 Annual American Society of Clinical Oncology (ASCO ) Meeting, 2018. e-Pub 2018.
Vidula N, Goga A, Hwang J, Liu MC, Park BH, Nanda R, Pohlmann PR, Storniolo AM, Brufsky A, Abramson VG, Rugo HS. A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies. 2018 Annual American Society of Clinical Oncology (ASCO ) Meeting, 2018. e-Pub 2018.
Sengupta S, Sevigny CM, Liu X, Jin L, Pohlmann PR, Clarke R. Targeting glycolysis enzyme, PFKFB3, in endocrine therapy resistant breast cancers. 2018 Annual American Association for Cancer Research (AACR) Meeting, 2018. e-Pub 2018.
Adams S, Diamond JR, Hamilton E, Pohlmann PR, TolaneyM, Chang CW, Zhang W, Iizuka K, Foster PG, Molinero L, Funke R, Powderly J. Atezolizumab (atezo) plus nab-paclitaxel (nab-pac) in metastatic triple-negative breast cancer (mTNBC): 2-year update from a ph 1b trial. 2018 Annual American Association for Cancer Research (AACR) Meeting, 2018. e-Pub 2018.
ElChaarani B, Stires H, Pohlmann PR, Riggins R. Pre-clinical analysis of the CDK4/6 inhibitor palbociclib in HER2-positive breast cancer. J Clin Oncol 356(15). e-Pub 2017.
Caleffi M, Burchardt NA, Scapin HP, Crivelatti I, Gomes CS, Gomes AL, Pohlmann PR. Patient-reported outcomes in metastatic breast cancer: QoL, needs, and expectations of survivors. 2017 American Society of Clinical Oncology (ASCO) Cancer Survivorship Symposium, 2017. e-Pub 2017.
Lynce F, Xiu J, Nunes MR, Swain SM, Gatalica Z, Isaacs C, Pohlmann P. Racial differences in the molecular landscape of breast cancer. 2016 Annual San Antonio Breast Cancer Symposium (SABCS), 2016. e-Pub 2016.
Pohlmann PR, Cruijsen H, Stam AGM, Lougheed SM, Eertwegh AJM, Hoekman K, Scheper R, Buter J, Hoeven JJM, Wall E, Pinedo HM, de Gruijl AT. Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune potentiation: Modern lessons from an old study. 2016 Annual San Antonio Breast Cancer Symposium (SABCS), 2016. e-Pub 2016.
Adams S, Diamond JR, Hamilton EP, Pohlmann PR, Tolaney SM, Molinero L, He X, Waterkamp D, Funke RP, Powderly JD. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). 2016 Annual American Society of Clinical Oncology (ASCO) Meeting, 2016. e-Pub 2016.
Adams S, Diamond J, Hamilton E, Pohlmann P, Tolaney S, Molinero L, Zou W, Liu B, Waterkamp D, Funke R, and Powderly J. Safety and clinical activity of atezolizumab (anti-PDL1 MAb) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer. 2015 Annual San Antonio Breast Cancer Symposium (SABCS), 2015. e-Pub 2015.
Shah A, Walsh A, Pohlmann PR, Skala M. Quantitative Autofluorescence Imaging Measures Early Response to Head and Neck Cancer Treatment In Vivo. Optics 2014, OSA Technical Digest (online) (Optical Society of America, 2014), 2014. e-Pub 2014.
Pohlmann PR, Miller TW, Blum DL, Pareh D, Yan H, Sutton CR, Dugger TL, Salazar LG, Wu W, Reyzer ML, Disis ML, Mernaugh R, Arteaga CL. Trastuzumab-reactive antibodies (TR-abs) in serum and trastuzumab (Tzb) benefit prediction in patients with HER2-overexpressing breast cancer. 2012 Markers in Cancer (ASCO, EORTC, NCI), 2012. e-Pub 2012.
Pohlmann PR. An active immune network is a surrogate marker for early tumor response to trastuzumab in a pre-clinical model of breast cancer. 2006 Annual San Antonio Breast Cancer Symposium (SABCS), 2006. e-Pub 2006.
•Caleffi M, Duarte Filho D, Skoniesky G, Bedin Jr A, Zignani JM, Antunes LP, Dias EC, Ashton-Prolla P, Weber B, Kivitz P, Graudenz MS, Pohlmann PR. The controversy of annual mammographic screening (AMS) for 40 to 69y-o women of Brazilian cohort of 10.000 underserved women. 2005 Annual San Antonio Breast Cancer Symposium (SABCS), 2005. e-Pub 2005.
Caleffi M, Ashton-Prolla P, Weber B, Zignani JM, Dias EC, Antues LP, Junior AB, Lisboa E, Graudenz M, Pohlmann PR, Filho DD. Breast cancer screening in 10,000 women of an underserved population in South Brazil: The NMAMAPOA Cohort. 2005 Annual American Society of Clinical Oncology (ASCO) Meeting, 2005. e-Pub 2005.
Pohlmann PR. Breast cancer epidemiology and annual mammographic screening (AMS) in 10,000 women of an underserved population in South Brazil. 2004 Annual San Antonio Breast Cancer Symposium (SABCS), 2004. e-Pub 2004.
Xavier N, Pohlmann PR, Menke CH, Biazus JV, Uchoa D, Detanico MF, Schwartsmann G, Cavalheiro JA, Cericatto R, Rabin EG, Bittelbrunn AC. Sentinel Lymph Node Predictors for Metastasis in Patients with T1C and T2 Breast Cancer. 13th International Congress on Senology (Breast Diseases), 2004. e-Pub 2004.
Toebak MJ, Pohlmann PR, von Blomberg BME, Scheper RJ, Rustemeyer T, Gibbs S. Chemokineproductie door `monocyte-derived´ dendritische cellen n blootstelling aan allergenen en irritanten. Nederlands Trjdsclinift Voor Dermatologie Venereologie 14(1):60, 2004. e-Pub 2004.
Nonnenmacher B, Perez LS, Bozzetti MC, Pohlmann PR, Cancian FS, Zettler CG, Mielzynska-Lohnas I, Dores GB. Prevalence of ASCUS and its relationship with HPV-DNA and cervical lesion. 20th International Papillomavirus Conference:228, 2002. e-Pub 2002.
Caleffi M, Duarte Filho D, Skoniesky G, Bedin Jr A, Zignani JM, Antunes LP, Dias EC, Ashton-Prolla P, Weber B, Kivitz P, Graudenz MS, PR <. The controversy of annual mammographic screening (AMS) for 40 to 69y-o women of Brazilian cohort of 10.000 underserved women. Can 2005 Annual San Antonio Breast Cancer Symposium (SABCS), 1999. e-Pub 1999.
Maino M, Mans DR, DiLeoni L, Lago S, Almeida JK, Pohlmann PR, Schunemann H, Ferreira-Filho AF, Kalakun L, Schwartsmann G. Phase II Trial of a 21-day Continuous Infusion of Topotecan in Advanced Pancreatic Carcinoma: a SOAD Trial. 1998 Annual Meeting of the American Society of Clinical Oncology (ASCO):295, 1998. e-Pub 1998.
Viegas MAV, DiLeoni L, Pohlmann PR, Loitzenbauer B, Kalakun L. Informed Consent in Early Clinical Trials with New Anticancer Agents: The SOAD Experience. 1998 Annual Meeting of the American Society of Clinical Oncology (ASCO):70a, 1998. e-Pub 1998.
Sander E, Pohlmann PR, Campos Jr O, Monego H, Rivoire W Grossmann OR, DiLeoni L, Loitzenbauer B, Kalakun L, Mans, DR, Schwartsmann G. Phase II Trial of Cisplatin and Decitabine in Patients with Advanced Cervical Cancer: a SOAD Trial. 1998 Annual Meeting of the American Society of Clinical Oncology (ASCO):374, 1998. e-Pub 1998.
Schwartsmann G, Menke CH, Caleffi M, Xavier N, Ferreira Filho AF, Schunemann H, Koya R, Stroda PR, Pohlmann PR, Venegas LF, Kalakun L. Phase II Trial of Taxol (T), Doxorubicin (D) Plus G-CSF in Patients (PTS) With Metastatic Breast Cancer (MBC). 1996 Annual Meeting of the American Society of Clinical Oncology (ASCO):126, 1996. e-Pub 1996.
Schwartsmann G, Mans DRA, Kalakun L, Grivich I, Schunemann, Ferreira Filho AF, Koya R, Lopes PRS, Pohlmann PR, Venegas LF, Pinto LB, Brunetto AL. Aumento dos níveis de etoposide no líquor em pacientes com gliomas refratários através do uso de altas-doses de tamoxifeno. 9º Congresso Brasileiro de Oncologia Clínica, 1995. e-Pub 1995.
Schwartsmann G, Scaletsky A, Jung F, Becker B, Gottfridson MJC, Machado VL, Pohlmann PR, Paglioli E, Oppitz P, Brunetto AL, Mans DRA. Farmacocinética do etoposide no líquido céfalo-raquidiano (LCR) de pacientes com gliomas refratários na presença de tamoxifeno. XIII Congresso Brasileiro de Cancerologia:17, 1994. e-Pub 1994.
Dietz J, Prolla JC, Pohlmann PR, Loss JF, Da Costa LA, Daudt AW, Grassi P, Achutti AC. Mortalidade por cancer de colo uterino no Rio Grande do Sul. Rev Assoc Med Bras (1992) 39(3):146-50, 1993. e-Pub 1993. PMID: 8281197.
Costa LA, Pohlmann PR, Machado V, Torres G, Yi Jong Wu V, Azevedo S. Linfoma Não-Hodgkin: apresentação exclusiva em retroperitônio. 8º Congresso Brasileiro de Oncologia Clínica:54, 1993. e-Pub 1993.
Pohlmann PR, Costa LA, Loss JF, Nicoletti C, Alves A, Dapper V, Ely D. Prevenção do câncer em estudantes de Medicina: relato final. 8º Congresso Brasileiro de Oncologia Clínica:67, 1993. e-Pub 1993.
Pohlmann PR. Cancer Prevention by Medical Students, final report. 8º Congresso Brasileiro de Oncologia Clínica, 1993. e-Pub 1993.
Pohlmann PR, Marzola B, Loss J, Polanczyk C, Zampese M. AIDS-Related Kaposi's Sarcoma in a Reference Hospital in the State of Rio Grande do Sul, Brazil: Survival Evaluation. VIII International Conference on AIDS / III STD World Congress, 1992. e-Pub 1992.
Pohlmann PR, Loss JF, Flores C, et al. Tabagismo em Porto Alegre: prevalência e o papel dos profissionais da saúde na prevenção. Actualización Científica. 8th Conferência Mundial sobre Tabagismo ou Saúde 2(6):4-5, 1992. e-Pub 1992.
Sander E, Sprinz E, Zampese M, Marzola B, Pohlmann PR, Brunetto AL, Kronfeld M, Schwartsmann G. Oral Etoposide in AIDS-Related Kaposi's Sarcoma: a Phase II Trial. VIII International Conference on AIDS / III STD World Congress:76, 1992. e-Pub 1992.
Pohlmann PR. AIDS-related malignancies. 7º Congresso Brasileiro de Oncologia Clínica, 1991. e-Pub 1991.
Pohlmann PR. Cervix Cancer Mortality in Rio Grande do Sul, Brazil. 7º Congresso Brasileiro de Oncologia Clínica, 1991. e-Pub 1991.
Pohlmann PR. Cancer Prevention: What do Medical Students know and how do they behave. 7º Congresso Brasileiro de Oncologia Clínica, 1991. e-Pub 1991.
Pohlmann PR, Loss JF, Wissmann Neto G, Marzola B, Vinholes J, Edelweiss MI, Robin Jr H, Sprinz E, Kronfeld M. Neoplasias associadas à Síndrome de Imunodeficiência Adquirida. 7º Congresso Brasileiro de Oncologia Clínica:17, 1991. e-Pub 1991.
Pohlmann PR, Costa LA, Loss JF, Dietz J, Prolla JC. Mortalidade por câncer de colo uterino no Rio Grande do Sul: aspectos epidemiológicos. 7º Congresso Brasileiro de Oncologia Clínica:38, 1991. e-Pub 1991.
Scroferneker ML, Ampessam M, Soares RS, Marques SMT, Cardoso AA, Horst JL, Loss JF, Pohlmann PR, Motta Neto AA, Edelweiss MI. Inquérito sorológico com antígenos de P. brasiliensis, H. capsulatum e S. schenckii em ratos (Rattus rattus) habitantes de uma mina de carvão. Mina do Leão - Brazil. III Encontro Nacional de Microbiologia Ambiental:73, 1990. e-Pub 1990.
Pohlmann PR, Loss JF, Flores C, Bolzzoni A, Duncan BB. Tabagismo em Porto Alegre: prevalência e o papel dos profissionais da saúde na prevenção. 6º Congresso Brasileiro de Oncologia Clínica:25, 1989. e-Pub 1989.
Pohlmann PR. Tobacco Abuse in Porto Alegre: Prevalence and Health Providers Role on Prevention. 6º Congresso Brasileiro de Oncologia Clínica, 1989. e-Pub 1989.

Book Chapters

Xiao, J, Pohlmann, PR, Schlegel, R, Agarwal, S. State of the Art in the Propagation of Circulating Tumor Cells, 247-274, 2023.
Lynce F, Pohlmann PR. Premalignant Breast Conditions and in Situ Disease,Part 3 Solid Malignancies. In: Breast Cancer. Elsevier Inc, 90-7, 2018.
Pohlmann PR, Tan A. Metastatic Breast Cancer, Part 3 Solid Malignancies. In: Breast Cancer. Elsevier Inc, 77-9, 2018.
Watson G, Goff L, Shi C, Pohlmann PR. HER2 (ERBB2) in Gastric Cancer. In: Cancer Genome, 2015.
Schwartsmann G, Cornelio D, Pohlmann PR. Oncology Section [Modulo Oncologia]. In: Tratado de Clinica Medica. 3, 2014.
Zimmer A, Pohlmann PR. Humoral Immunity [Imunidade Humoral]. In: Imunologia Básica e Aplicada. 2, 2007.
Schwartsmann G, Cornelio D, Pohlmann PR. The Basis for Chemotherapy [Bases da Quimioterapia]. In: Tratado de Clinica Medica. 2, 2007.
Girardi F, Pohlmann PR. Cellular Immunity [Imunidade Celular]. In: Imunologia Básica e Aplicada. 2. Segmento Farma, 2007.
Girardi F, Pohlmann PR. Tumor Immunology [Imunologia Tumoral]. In: Imunologia Básica e Aplicada. 2. Segmento Farma, 2007.
Pohlmann PR. Breast Cancer Molecular Biology [Biologia Molecular do Câncer de Mama]. In: A Mama em Imagens, 2006.
Pohlmann PR, Schwartsmann G. New Combined Therapies [Novas Combinações Terapêuticas]. In: Ferreira CG, Rocha JC. Oncologia Molecular. 1, 2004.
Pohlmann PR. Chemoprevention [Químio-Prevenção]. In: Cancerologia para Leigo. 1, 2001.
Eckert GU, Barrionuevo AA, Pohlmann PR. Lymphatic Organs [Órgãos Linfóides]. In: Imunologia Básica e Aplicada. 1, 1998.
Pohlmann PR. The Cells of Immune System [Células do Sistema Imune]. In: Imunologia Básica e Aplicada. 1, 1998.
Furian TQ, Pohlmann PR. Tumor Immunology [Imunologia dos Tumors]. In: Imunologia Básica e Aplicada. 1, 1998.
Pohlmann PR. Tumor Immunology [Imunologia dos Tumores]. In: Notas de Imunologia, 1996.
Pohlmann PR. Lymphatic Organs [Órgãos Linfóides]. In: Notas de Imunologia, 1996.
Pohlmann PR. The Cells of Immune System [Células do Sistema Imune]. In: Notas de Imunologia, 1996.
Crestani J, Pohlmann PR, Scroferneker ML. Type I Hypersensitivity reactions [Hipersensibilidade tipo I]. In: Notas de Imunologia, 1996.
Pohlmann PR, Venegas LF, Ferreira Filho AF, Machado VL, Fleck J. Suspeita de Neoplasia. In: Medicina Interna: Do Diagnóstico ao Tratamento, 1995.
Venegas LF, Pohlmann PR, Machado VL. Renal Cell carcinoma [Carcinoma de Células Renais]. In: Medicina Interna: Do Diagnóstico ao Tratamento, 1995.
Pohlmann PR, Ferreira Filho AF, Schwartsmann G. Breast Cancer Chemotherapy [Quimioterapia do Câncer de Mama]. In: Mastologia Atual, 1994.

Books (edited and written)

Scroferneker ML, Pohlmann PR. Basic and Applied Immunology [Imunologia Básica e Aplicada]. Ed(s) 1 ED. Sagra Luzzatto, 1998.

Letters to the Editor

Savani BN, Pohlmann PR, Jagasia M, Chinratanalab W, Kassim A, Engelhardt B, Greer J, Schuening F, Goodman S. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?. Blood 113: 6263-4, 2009.
Pohlmann PR, Mernaugh RL, Goff LW. Chemotherapy and immunotherapy in metastatic colorectal cancer. N Engl J Med 360: 2134; author reply 2135-6, 2009.

Less

Selected Presentations & Talks

Local Presentations

2024. Breast cancer treatment landscape and opportunities for clinical trials/CME. Invited. ICT Grand Rounds. Houston, Texas, US.
2024. Keynote Speaker: Development of Vaccines in Adjuvant/Advanced Breast Cancer Settings/CME. Invited. Updates on Advanced Breast Cancer. Houston, Texas, US.
2022. HALT-D: A Randomized Open Label Phase 2 Study of Crofelemer for the Prevention of Chemotherapy-induced Diarrhea (CID) in Patients with Breast Cancer Receiving Trastuzumab, Pertuzumab and a Taxane. Invited. Crofelemer Investigators and CINV Management. Houston, TX, US.
2019. Pathways to Collaboration: Breast Cancer Translational Research/CME. Invited. The University of Texas, MD Anderson Cancer Center. Houston, TX, US.
2017. Breast Cancer. Invited. Journal Club. Washington, DC, US.
2012. Journal Club Discussant: HER2 positive gastric cancer/ The ToGA trial. Invited. Journal Club. Nashville, TN, US.
1994. Diabetes Mellitus. Invited. Curso Tópicos em Medicina Interna X Semana Acadêmica da Medicina. Porto Alegre, BR.
1994. Urinary Tract Infection. Invited. Curso Tópicos em Medicina Interna X Semana Acadêmica da Medicina. Porto Alegre, BR.
1993. AIDS. Invited. Curso de Clínica Médica da Semana Acadêmica. Porto Alegre, BR.
1993. BLS and First Aid. Invited. Atividades Relacionadas à Segurança e Prevenção de Acidentes no Instituto de Química. Porto Alegre, BR.
1990. Breast Self-Exam in Medical Students. Invited. Primeiro Encontro de Educação em Controle do Câncer. Porto Alegre, BR.

National Presentations

2024. Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated phase I department at The University of Texas MD Anderson Cancer Center. Poster. 2024 ASCO Annual Meeting. Chicago, IL, US.
2024. Future directions in breast cancer treatment. Invited. MDHealth Brazil AZ & UT MDACC BMO Conference. Houston, TX, US.
2024. Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd). Poster. 2024 ASCO Annual Meeting. Chicago, IL, US.
2024. Response to RAF/MEK/ERK inhibitors in patients with RAS altered and wild-type tumors. Poster. 2024 ASCO Annual Meeting. Chicago, IL, US.
2024. A phase 1 study of the BET inhibitor ZEN003694 in combination with the MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer (NCI number 10449). Poster. 2024 ASCO Annual Meeting. Chicago, IL, US.
2024. A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors. Poster. 2024 ASCO Annual Meeting. Chicago, IL, US.
2024. Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial. Poster. 2024 ASCO Annual Meeting. Chicago, IL, US.
2024. Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study. Poster. 2024 ASCO Annual Meeting. Chicago, IL, US.
2024. Zanidatamab in Early-Stage Breast Cancer: Reducing Toxicity in a Curative Setting. Invited. Zanidatamab R&D Day. Palo Alto, CA, US.
2024. PRE-I-SPY / I-SPY-P1 update. Invited. I-SPY Science Day. San Diego, CA, US.
2024. Adjuvant study for patients with MRD. Invited. I-SPY Science Day. San Diego, CA, US.
2024. Breast Cancer Review: Updates on HR+HER2- Breast Cancer/CME. Invited. 24th Annual Hematology and Breast Cancer Update. Portland, OR, US.
2023. Considerations in TNBC Neoadjuvant Therapy. Invited. OncLive Sate of the Science Summit™: Breast Cancer. Houston, TX, US.
2023. A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors. Poster. 2023 ASCO Annual Meeting. Chicago, IL, US.
2023. A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors. Poster. 2023 ASCO Annual Meeting. Chicago, IL, US.
2023. Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival. Poster. 2023 ASCO Annual Meeting. Chicago, IL, US.
2023. A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i). Poster. 2023 ASCO Annual Meeting. Chicago, IL, US.
2023. Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study. Invited. 2023 ASCO Annual Meeting. Chicago, IL, US.
2023. Landscape of Novel Therapies for HER2+ Breast Cancer/CME. Invited. TBCRC HER2 WG Breakout Session. Dallas, TX, US.
2023. TALAVE: Induction talazoparib (tala) followed by combined tala and avelumab in patients (pts) with advanced breast cancer (ABC). Poster. Proceedings of the American Association for Cancer Research Annual Meeting. Orlando, FL, US.
2022. Discussant at Spotlight Session 18: Updates and New Therapies for HER2 Positive Disease/CME. Invited. SABCS. San Antonio, TX, US.
2021. Lombardi Translational Research. Invited. IIT (TRI) Meeting. Washington, US.
2020. HER2 Positive Breast Cancer. Invited. OncLive Institutional Perspectives in Cancer: Breast. Washington, DC, US.
2019. Breast Cancer Management with Immunotherapy/CME. Invited. Women's Malignancies Seminar Series. Baltimore, MD, US.
2019. Opportunities for Translational Research in Breast Cancer/CME. Invited. Sylvester Comprehensive Cancer Center. Miami, FL, US.
2019. Wrap‐Up/Q&A. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2019. Session 8: Clinical Decision Making – HER2 and Hormone Receptor Status in Recurrent and Metastatic Breast Cancer. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2019. Session 1: Patient, Caregiver, and Family Experience – Impact of Diagnosis and Treatment. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2019. Welcome, Introductions, and Program Overview. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2019. HER2 Positive Breast Cancer/CME. Invited. Tumor Cell Biology Series. Washington, DC, US.
2019. Session 6: Clinical Case Breakouts – Early and Locally Advanced Breast Cancer. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2019. Session 10: Clinical Case Breakouts – Recurrent and Metastatic Breast Cancer. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2019. Session 11: Bringing It All Together. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2019. New anti-HER2 therapies. Invited. Oncology Meeting Innovations. New York, NY, US.
2019. Management of early stage HER2 positive breast cancer. Invited. Oncology Meeting Innovations. New York, NY, US.
2018. Expert Forum on Breast Cancer/CME. Invited. Omni Hotel. Dallas, TX, US.
2018. A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers. Invited. 2018 ASCO Annual Meeting. Chicago, IL, US.
2018. Session 11: Treatment and Treatment Decisions: HER2-Positive Recurrent and Metastatic Breast Cancer. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2018. Session 10: Hormone Receptor Positive, HER2-Negative Recurrent and Metastatic Breast Cancer. Invited. ASCO Advantage: BREAST CANCER. Alexandria, VA, US.
2018. Session 6: Treatment and Treatment Decisions: Early and Locally Advanced Breast Cancer. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2018. Session 1: Patient, Caregiver/Family Experience – Impact of Diagnosis and Treatment. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2018. Session 10: Hormone Receptor Positive, HER2-Negative Recurrent and Metastatic Breast Cancer. Invited. ASCO Advantage: BREAST CANCER. Alexandria, VA, US.
2018. Session 7: Small Group Work: Clinical Cases: Early and Locally Advanced Breast Cancer. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2018. Session 14: Small Group Work: Clinical Cases: Recurrent and Metastatic Breast Cancer. Invited. ASCO Advantage: BREAST CANCER Course. Alexandria, VA, US.
2018. Breast. Invited. ION Solutions Oral Therapies Meeting. Frisco, TX, US.
2018. Breast Cancer/CME. Invited. Grand Rounds. Washington, DC, US.
2017. Experiences from the Clinic: Breast and Gastrointestinal Cancers. Invited. Rockville, MD, US.
2017. Cancer Treatment Induced Diarrhea: Clinical Implications and the Regulatory Perspective. Invited. Rockville, MD, US.
2016. Racial differences in the molecular landscape of breast cancer. Poster. 2016 Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX, US.
2016. Discussant: Fellows Poster Walk Discussion Session. Invited. 2016 ASCO Annual Meeting. Chicago, IL, US.
2015. Tumor profiling of 1168 geriatric breast tumors. Conference. American Society of Clinical Oncology (ASCO) Breast Symposium. San Francisco, CA, US.
2014. Journal Club Discussant: Breast Cancer. Invited. Journal Club. Washington, DC, US.
2013. Esophageal Cancer: Where are we? Where will we be in 2020? / CME. Invited. Fifth Annual Advances in the Management of Thoracic Diseases. Franklin, TN, US.
2012. Esophageal Cancer and Metastasis/CME. Invited. Fox and Hedgehog Conference. Nashville, TN, US.
2012. Trastuzumab-reactive antibodies in serum and trastuzumab benefit prediction in patients with HER2-overexpressing breast cancer. Conference. 2012 Markers in Cancer (ASCO, EORTC, NCI). Hollywood, FL, US.
2012. Predictors of response in serum: Anti-trastuzumab antibodies and breast cancer. Invited. Lombardi Comprehensive Cancer Center. Washington, DC, US.
2012. Mouse Models for Chemotherapy Sensitivity/CME. Invited. Fox and Hedgehog Conference. Nashville, TN, US.
2012. HER2 Positive Gastric Cancer/The ToGA Trial. Invited. Journal Club. Nashville, TN, US.
2011. Do Autoantibodies Influence the Clinical Response to Trastuzumab in HER2 Positive Breast Cancer? / CME. Invited. Vanderbilt Neurocardiology Grand Rounds. Nashville, TN, US.
2011. Personalized Medicine: Serum biomarkers to predict trastuzumab resistance in breast cancer. Invited. Lester and Sue Smith Breast Center. Houston, TX, US.
2010. Anti-trastuzumab Antibodies / CME. Invited. Rheumatology Grand Rounds. Nashville, TN, US.
2009. Trastuzumab resistance mechanisms. Invited. National Cancer Institute/National Institutes of Health (NCI/NIH). Bethesda, MD, US.
2005. Angiogenesis. Invited. 2nd Simpósio de Imunologia: Imunobiologia dos Tumores. Botucatu, BR.
2005. Clinical Research Methods. Invited. Medical Oncology and Radiation Oncology Fellowship Lectures. Porto Alegre, BR.
2005. Molecular Biology of Breast Cancer. Invited. XXVIII Curso de Radiologia da Mama. Porto Alegre, BR.
2005. Breast Cancer Epidemiology. Invited. XXVIII Curso de Radiologia da Mama. Porto Alegre, BR.
2004. Breast Cancer Epidemiology. Invited. XXVII Curso de Radiologia da Mama. Porto Alegre, BR.
2004. Neoadjuvant treatment of locally advanced breast cancer. Invited. Topicos em Oncologia e Hematologia. Porto Alegre, BR.
2004. Molecular Biology of Breast Cancer. Invited. Topicos em Oncologia e Hematologia. Porto Alegre, Oncology Division, HCPA/UFRGS, BR.
2004. Breast Cancer Epidemiology. Invited. XXVI Curso de Radiologia da Mama. Porto Alegre, BR.
2003. Translational Opportunities During Neoadjuvant Therapy for Breast Cancer Patients. Invited. Vanderbilt University Medical Center. Nashville, TN, US.
1998. Neoadjuvant treatment for locally advanced breast cancer. Invited. Tópicos em Oncologia e Hematologia. Porto Alegre, US.
1998. Chemotherapy for Solid Tumors. Invited. Curso de Quimioterapia Antineoplásica da Semana Academica de Estudos Farmaceuticos/1998. Porto Alegre, BR.
1998. Breast Cancer Biology. Invited. Tópicos em Oncologia e Hematologia. Porto Alegre, BR.
1996. Breast Cancer Epidemiology. Invited. Curso de Radiologia da Mama. Porto Alegre, BR.
1991. Cervix Cancer Mortality in Rio Grande do Sul, Brazil. Invited. 7º Congresso Brasileiro de Oncologia Clínica, BR.
1989. Tobacco in Porto Alegre: Prevalence and Prevention. Conference. Curso Básico em Oncologia, National Campaign Against Cancer – Oncology Program. Porto Alegre, BR.

International Presentations

2024. Future Directions in Breast Cancer Treatment. Invited. MDHealth Brazil AZ & UT MDACC BMO Conference. Houston, US.
2024. Discovering the Optimal Clinical Setting for Achieving Positive & Accurate Results to Streamline Candidate Approval: Breast Cancer. Invited. 7th International NeoAntigen Summit. Amsterdam, NL.
2022. Precision medicine in the treatment of patients with breast cancer. Invited. 2022 IC PerMed International. Paris, FR.
2020. Metastatic TNBC Treatment Update. Invited. Virtual Training Central America and Caribbean (Remote Session). Washington, US.
2019. Revolutionizing the Paradigm of Triple Negative Breast Cancer Management with Immunotherapy. Invited. Immunotherapy Review Central America and Caribe. Miami, US.
2018. Cancer Immunotherapy as an emerging therapeutic option in Triple Negative Breast Cancer. Invited. Chang-Gung Memorial Hospital. Taoyuan City, TW.
2018. Triple Negative Breast Cancer (Keynote Speaker). Invited. Cancer Immunotherapy Symposium. Zhongzheng, TW.
2018. Cancer Immunotherapy in Breast Cancer. Invited. Koo Foundation Sun Yat-Sen Cancer Center. Beitou, TW.
2018. Round table on TNBC Immunotherapy. Invited. Cancer Immunotherapy Symposium. Zhongzheng, TW.
2017. Innovation Process in Oncology. Invited. 6th Mission of Studies on Innovation for Brazilian House of Representatives and Senators. Washington, US.
2016. Medical Oncology Innovation, Development, and Validation in Brazil and in the USA: When Differences are Opportunities. Invited. BEN Talks. Washington, US.
2005. Oportunidades para pesquisa e assistência com parceirias público-privadas: um modelo para países em desenvolvimento.A Coorte NMAMAPOA. Invited. I Congresso Internacional de Mastologia. Porto Alegre, BR.
2004. Angiogenesis and Antiangiogenesis Signal in Tumor Progression. Invited. 1st Latin American Conference on Lung Cancer. Guarujá, BR.
2004. The Spinoza Trial: A phase III trial. Invited. Investigators Meeting. New Orleans, US.
2003. The Spinoza Trial: A Phase III Trial. Invited. Investigators Meeting. Chicago, US.
2002. The Spinoza Trial: A Phase III Trial. Invited. Investigators Meeting. Orlando, US.

Formal Peers

2019. Session 11: Bringing It All Together. Visiting. ASCO. Alexandria, VA, US.
2019. Welcome, Introductions, and Program Overview. Visiting. ASCO. Alexandria, VA, US.
2019. Wrap‐Up/Q&A. Visiting. ASCO. Alexandria, VA, US.
2018. Round table on TNBC Immunotherapy (Panelist). Visiting. National Taiwan University Hospital. Zhongzheng, TW.
2018. Session 7: Small Group Work: Clinical Cases: Early and Locally Advanced Breast Cancer. Visiting. ASCO. Alexandria, VA, US.
2017. Breast Cancer (Journal Club Discussant). Visiting. Georgetown University. Washington, DC, US.
2016. Fellows Poster Walk Discussion Session (Discussant). Visiting. 2016 Annual American Society of Clinical Oncology (ASCO) Meeting. Chicago, IL, US.
2012. HER2 Positive Gastric Cancer/The ToGA Trial. Visiting. Vanderbilt University. Nashville, TN, US.
1994. Urinary Tract Infection. Visiting. Centro Acadêmico Sarmento Leite, UFRGS. Porto Alegre, Rio Grande do Sul, BR.
1994. Diabetes Mellitus. Visiting. Centro Acadêmico Sarmento Leite, UFRGS. Porto Alegre, BR.
1993. Cancer Screening. Visiting. Breast Cancer Advocay Group. Novo Hamburgo, Rio Grande do Sul, US.
1993. AIDS. Visiting. Centro Acadêmico Sarmento Leite, UFRGS. Porto Alegre, BR.
1993. BLS and First Aid. Visiting. Instituto de Química, UFRGS. Porto Alegre, US.

Less

Grant & Contract Support

Date:	2024 - Present
Title:	Discovery of non-canonical antigens in breast cancer for development of novel T cell therapies
Funding Source:	DOD
Role:	Co-PI
ID:	BC240730P1

Date:	2022 - 2022
Title:	The SIK2 Inhibitor GRN-300 Enhances Olaparib Sensitivity and TCell Functions in Triple-Negative Breast Cancer
Funding Source:	DOD
Role:	Co-PI
ID:	BC220820P1

Date:	2021 - 2022
Title:	Evaluating the safety of weekly paclitaxel with trastuzumab duocarmazine (SYD985) in patients with metastatic cancer: A Phase I/Ib trial
Funding Source:	Byondis (formerly Synthon Biopharmaceuticals)
Role:	PI
ID:	PRE-ISPY-P1-01

Date:	2019 - 2020
Title:	Conditionally reprogrammed cell (CRC) cultures originated from circulating tumor cells from patients with different solid malignancies
Funding Source:	Partners in Research, Georgetown University
Role:	PI
ID:	PIR

Date:	2018 - 2021
Title:	LCCC #2017-1033, Preoperative palbociclib in women with DCIS of the breast that are candidates for surgery, a translational study
Funding Source:	InspIIRe Award - Pfizer Inc
Role:	PI
ID:	WI223281

Date:	2017 - 2021
Title:	LCCC# STUDY00000057, A Phase I trial of Palbociclib and Bosutinib with Fulvestrant in patients with metastatic hormone receptor positive and HER2 negative breast cancer refractory to an aromatase inhibitor and a CDK4 6 inhibitor
Funding Source:	2017 ASPIRE Award Oncology Hematology
Role:	PI
ID:	WI231696

Date:	2017 - 2021
Title:	OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Funding Source:	Lombardi Comprehensive Cancer Center/BMS
Role:	Mentor
ID:	LCCC #2017-1535

Date:	2016 - 2021
Title:	Optimizing Targeted Breast Cancer Therapy by Mathematical Modeling and Experimental Studies
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	R01CA201092-01

Date:	2015 - 2018
Title:	LCCC#2015-0547 Diarrhea Prevention and Prophylaxis with Crofelemer in HER2 + breast cancer patients receiving pertuzumab, trastuzumab and docetaxel or Paclitaxel: HALT-D
Funding Source:	Genentech/Roche
Role:	PI
ID:	ML29886

Date:	2011 - 2012
Title:	RTOG-1010 A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Funding Source:	Research Allocation Committee (RAC) Vanderbilt
Role:	PI
ID:	RAC Funding

Date:	2008 - 2008
Title:	The Immunological Consequences of Isoketal Formation in Animals
Funding Source:	Vanderbilt University Medical Center
Role:	Co-PI
ID:	Toxicology Center Pilot Project #3

Date:	1991 - 1991
Title:	Cancer Information Update
Funding Source:	FAPERGS (Foundation for the Support of Research in the State of Rio Grande do Sul)
Role:	Co-I

Date:	1990 - 1991
Title:	Antigens of Onchocerca cervicalis, and their diagnostic use
Funding Source:	PROPESP - Institute of Research and Post-Graduation, UFRGS
Role:	Co-I

CV information above last modified March 03, 2025

Paula R. Pohlmann, M.Sc., Ph.D.

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Paula R. Pohlmann, M.Sc., Ph.D.

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer